In recent years, the treatment of cancer has shifted from a one-size-fits-all approach using chemotherapy (which kills all cells including healthy cells) to targeted therapy (which kills only cancer cells and have fewer side effects). Based on clinical studies, patients with certain genetic mutations in their tumors have been shown to respond better to specific targeted drugs. Our diagnostic tests identify clinically-relevant genetic mutations in each tumor to find the right drug for the patient. Our tests can also help to monitor treatment response and signs of cancer recurrence.
Flagship blood test that covers a wide range of clinically-relevant companion biomarkers
In-depth genomic profiling of the hematological malignancy including myeloid and lymphoid neoplasms
Comprehensive genomic profiling of more than 500 genes in tissue specimens
Tissue PD-L1 Triplex™
Quantitative Multiplex IHC for 3 PD-L1 clones SP142, SP263 and 22C3 in 1 tissue sample